meta|IO

Evidence base on efficacy and safety of
Immuno-Oncology drugs

Global living systematic review and meta-analysis of RCTs

Latest studies

Li, 2024

breast cancer - triple negative

camrelizumab plus SOC

KEYNOTE-119 PD-L1 positive (CPS = 1 or more), 2019

la/mBC - TNBC - L2 - PDL1 positive

pembrolizumab alone

KEYNOTE-119 PD-L1 positive (CPS = 10 or more), 2019

la/mBC - TNBC - L2 - PDL1 positive

pembrolizumab alone

IMpassion-132, PD-L1 positive population, 2024

la/mBC - TNBC - L2 - PDL1 positive

atezolizumab plus SoC

A-Brave Stratum A, 2024

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)

avelumab alone

NeoTrip Michel Angelo, 2022

es-BC - TNBC - NA - all population

atezolizumab plus SoC

TORCHLIGHT PDL 1 positive population, 2024

la/mBC - TNBC - L1 - PDL1 positive

nab-paclitaxel plus toripalimab

TORCHLIGHT, 2024

la/mBC - TNBC - L1 - all population

nab-paclitaxel plus toripalimab

ICON, 2024

la/mBC - HR positive - L2 - all population

nivolumab plus ipilimumab

Saphir02 Breast-Immuno, 2021

mBC - HER 2 negative

durvalumab alone

Modul Cohort 4, 2023

metastatic/advanced - colorectal cancer (mCRC)

atezolizumab plus cometinib

CONTACT-03, 2023

metastatic/advanced RCC (mRCC) - 2nd line (L2)

atezolizumab plus cabozantinib

CheckMate 9DW, 2024

mHCC - 1st line (L1)

nivolumab plus ipilimumab plus SoC

CARES-310, 2023

mHCC - 1st line (L1)

VEGF(R) inhibitor

IMbrave050, 2023

mHCC - (neo)adjuvant (NA)

atezolizumab plus bevacizumab

Wang, 2024

mHCC - (neo)adjuvant (NA)

sintilimab

RATIONALE 301, 2024

mHCC - 1st line (L1)

Tislelizumab

RUBY (part 2), 2024

endometrial cancer

niraparib

MITO END-3, 2023

endometrial cancer

avelumab plus SoC

DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023

endometrial cancer

durvalumab plus olaparib plus SoC

457
treatments 		  384
studies 		  1344
references
This project is supported by H2020 Qualitop, an EU-funded project, Hospices Civils de Lyon and CNRS UMR5558 LBBE.
     

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons